Show simple item record

dc.contributor.authorWang, Q.
dc.contributor.authorWang, Q.
dc.contributor.authorWang, S.F.
dc.date.accessioned2019-07-15T16:12:11Z
dc.date.available2019-07-15T16:12:11Z
dc.date.issued2017
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85028649011&doi=10.3747%2fco.24.3561&partnerID=40&md5=8d436bd55e2ee2b9afd3dbf5057576ac
dc.identifier.urihttp://hdl.handle.net/10713/9933
dc.description.abstractBackground: The concept of maintenance therapy in cancer treatment is currently under debate because of modest survival benefits, added toxicity, economic considerations, and quality-of-life concerns. Traditional Chinese Medicine (tcm) is widely used in China for cancer patients, offering the advantages of low toxicity and enhancement of quality of life. However, no systematic reviews or meta-analyses have assessed the role of tcm as maintenance treatment for non-small-cell lung carcinoma. Methods: We searched the Chinese Biomedical Literature Database, the China National Knowledge Infrastructure, PubMed, embase, and the Cochrane Library databases for all eligible studies. The endpoints were overall survival (os), progression-free survival (pfs), the 1-year and 2-year survival rates, and performance status. Our meta-analysis used a fixed-effects model and a random-effects model for heterogeneity in the Stata software application (version 11.0: StataCorp LP, College Station, TX, U.S.A.), with the results expressed as hazard ratios (hrs) or risk ratios (rrs), with their corresponding 95% confidence intervals (95% cis). Results: Sixteen randomized studies representing 1150 patients met the inclusion criteria. Compared with best supportive care, observation, or placebo, tcm as maintenance treatment was associated with a significant increase in os (hr: 0.49; 95% ci: 0.35 to 0.68; p < 0.001), pfs (hr: 0.66; 95% ci: 0.51 to 0.84; p = 0.001), and 2-year survival rate (rr: 0.63; 95% ci: 0.44 to 0.92, p = 0.017), and a significant improvement in performance status (rr: 0.68; 95% ci: 0.61 to 0.75; p < 0.001). Conclusions: For patients who show non-progression—including stable disease, partial response, or complete response—after first-line chemotherapy, including those with poor quality of life, oral Chinese herbal medicine can be considered an efficient and safe maintenance therapy strategy. Copyright 2017 Multimed Inc.en_US
dc.description.sponsorshipThis study was funded by the Shanghai Minhang Municipal Planning Commission of Science and Research Fund (no. 2014MW24); the National Natural Science Fund (no. 81072740); the National Scientific Research Project of National Traditional Chinese Medicine (no. 201307006); the Science and Technology Commission of Shanghai Municipality (nos. 16401970700, 16401970701, 16401970704); and the Fund of Shanghai University of Traditional Chinese Medicine (no. 2015YSN37).en_US
dc.description.urihttps://www.doi.org/10.3747/co.24.3561en_US
dc.language.isoen_USen_US
dc.publisherMultimed Inc.en_US
dc.relation.ispartofCurrent Oncology
dc.subjectAdvanceden_US
dc.subjectIntegrative oncologyen_US
dc.subjectMaintenance therapyen_US
dc.subjectNon-small-cell lung canceren_US
dc.subjectTraditional Chinese medicineen_US
dc.titleOral Chinese herbal medicine as maintenance treatment after chemotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysisen_US
dc.typeArticleen_US
dc.identifier.doi10.3747/co.24.3561
dc.identifier.pmid28874897


This item appears in the following Collection(s)

Show simple item record